#France #UroMems #Grenoble #UroActive #urinary incontinence

UroMems Unveils Breakthrough Results in Clinical Study of UroActive® Implant

UroMems, a pioneering global company specializing in innovative mechatronic solutions, has made significant strides in treating stress urinary incontinence (SUI) with their recently developed UroActive® smart implant. Announced on February 20, 2025, this groundbreaking technology aims to provide effective relief to millions of women suffering from this condition, which significantly impacts their quality of life.

Milestone Achievement in Women’s Health

During an initial six-month clinical feasibility study, all participants demonstrated successful outcomes after receiving the UroActive® implant. This historic trial was the first of its kind to focus on female patients and has set a new standard for the treatment of SUI. The results will be presented by Professor Emmanuel Chartier-Kastler at the upcoming Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) meeting in Palm Springs, California, on February 27.

CEO and co-founder Hamid Lamraoui expressed his enthusiasm, stating, "Women are disproportionately affected by stress urinary incontinence, and our mission is to provide an effective solution where none currently exists. Thanks to the dedication of our study participants and their physicians, we are closer than ever to offering a life-changing option for millions."

Patients’ Positive Experiences

The clinical study evaluated a cohort of twelve patients who underwent implantation of the UroActive® system. Notably, these women reported transformational experiences post-implantation, indicating a return to normalcy after long struggles with incontinence.

One participant remarked, "I feel like I’m living life again. It’s a world of difference!" Such feedback highlights the pivotal role UroActive® can play in enhancing the quality of life for individuals affected by urinary incontinence.

Innovative Technology at Work

UroActive® is not just any artificial urinary sphincter; it is the first automatic and intelligent system of its kind. Utilizing advanced myoelectromechanical systems (MEMS), the device is strategically placed around the urethra and adapts to the patient's activity levels, eliminating the need for manual adjustments. This innovation aims to provide greater patient comfort, ease of use, and an improved quality of life compared to existing options.

Future Implications and Continued Research

The impact of SUI is profound, with estimates indicating that around 40 million Americans and 90 million Europeans are affected. Common repercussions include not only physical discomfort but also emotional challenges such as depression, low self-esteem, and social stigma. UroMems’ commitment to continued research and development in this field is crucial for addressing the unmet needs of these individuals.

In addition to the promising initial feasibility study results, UroMems recently secured $47 million in funding, further enabling the advancement of UroActive® and its potential market introduction. Importantly, UroActive® has not yet received FDA approval and remains unavailable for sale in the United States or the EU, thus highlighting the ongoing nature of this critical medical endeavor.

About UroMems

Incorporating a robust intellectual property framework with over 150 successfully granted patents, UroMems is dedicated to optimizing patient safety, surgical performance, and comfort through its unique mechatronic platform. With ongoing support from the European Innovation Council and France 2030, UroMems continues to innovate in the fight against SUI. To learn more about their initiatives and the UroActive® device, visit www.uromems.com.

For media inquiries, contact Shelli Lissick at [email protected] or call 651-276-6922.